- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05785221
Lifestyle Intervention on Metabolic Homeostasis
Exploratory Personalized Lifestyle Intervention on Metabolic Homeostasis in Overweight or Obese Chinese Population
Study Overview
Status
Detailed Description
The objectives of this study are to 1) characterize metabolic homeostasis under resting and exercise conditions, 2) to explore the potential impact factors on metabolic homeostasis, and 3) to investigate whether personalized nutritional and lifestyle weight reduction intervention can improve metabolic health in overweight or obese Chinese individuals and how is it comparable to healthy normal weight Chinese population.
In this study, 84 overweight or obese participants (BMI ≥ 24 kg/m2) and 28 normal weight participants (18.5 ≤ BMI<24 kg/m2) will be recruited and receive 12-week personalized weight reduction or weight maintenance nutritional and lifestyle interventions. Before and after the 12-week interventions, metabolic homeostasis will be used to characterize metabolic health and to be determined using comprehensive measurements of dynamic changes in postprandial metabolic responses (including energy metabolism, multiple clinical biomarkers, metabolomic signatures, gut microbiota, genetic signatures etc.) after the standardized mixed-nutrient dietary challenges (75 g glucose, 60 g fat and 20 g protein) in whole room indirect calorimeter under both resting and exercise conditions. In addition, data from dietary intake, anthropometric measurements, body composition, psychosocial measures, behavior questionnaires and 14-day continuous glucose monitoring will also be collected to characterize metabolic homeostasis. During the interventions, participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions, and an application-connected scale will be used to monitor their weight changes during interventions. The study's protocol has been approved by the Ethics Committee of Sir Run Run Shaw Hospital.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wanhui Kang, PhD
- Phone Number: +86 86081210
- Email: kangwanhui@ucas.ac.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310024
- Recruiting
- Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences
-
Principal Investigator:
- Xu Lin, PhD
-
Contact:
- Wanhui Kang, PhD
- Email: kangwanhui@ucas.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 20-70 years of age, inclusive
- BMI ≥ 24kg/m2
- Not in other clinical studies currently or in the past three months
Exclusion Criteria:
- Fasting glucose >7.0mmol/L or diagnosed diabetes or taking insulin or other blood glucose-lowering drugs
- Blood pressure > 160/100 mmHg; diagnosed phase II or III hypertension or cannot decrease SBP under 160mmHg after anti-hypertension drugs
- Fasting blood TG≥ 5.7 mmol/L or fasting LDL-C≥ 4.9 mmol/L or cannot control TG < 5.7 mmol/L or LDL-C < 4.9 mmol/L after taking lipid lowering drugs
- Pregnant or lactating
- Attempting to change body weight in the past 3 months
- Use of antibiotic in the preceding 3 months for 3-serial days
- Use of estrogen therapy or hormonal drugs in the preceding 6 months
- Smokers
- History of alcohol abuse or other substance abuse (Alcohol abuse is defined as regular alcohol consumption > 40 g/day for females or > 80 g/day for males)
- Severe renal disease or liver disease
- Severe gastrointestinal diseases
- Surgical events preceding 1 year (except appendicitis or hernia surgery)
- Severe cardiovascular or cerebrovascular diseases
- Implantation of heart stent or any device containing metal material
- Cancer or receiving radiotherapy and chemotherapy within 5 years
- Hyperthyroidism or hypothyroidism
- Suffering from AIDS, hepatitis A, hepatitis B and other infectious diseases
- Claustrophobia
- Physical disability
- Any mental disorders or current use of antidepressants
- Cognitive disability
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Healthy Comparators
They will receive general lifestyle and nutritional education.
|
Participants will receive general dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
|
Experimental: Overweight/Obese Group
They will receive personalized nutritional and lifestyle weight reduction intervention including dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians.
|
Participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians.
APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions and APP-connected scale will be used to monitor their weight changes during interventions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Metabolic Homeostasis Score at 12 Weeks
Time Frame: Baseline and Week 12
|
A metabolic homeostasis score is a composite score that includes aggregated changes in blood biomarkers (metabolites or biomarkers or index involved in carbohydrates metabolism such as glucose, C-peptide, Matsuda index etc.; metabolites or biomarkers involved in lipid metabolism such as high-density lipoprotein cholesterol, total cholesterol, triglyceride etc.; metabolites or biomarkers involved in protein/vitamin metabolism such as creatinine; inflammatory or cytokines such as interleukin-6 etc.; hormones; anthropometric measures etc.). The metabolic homeostasis score is a composite score, that is calculated by the average of the scores of above-mentioned features using a certain computational algorithm. The larger the metabolic homeostasis score is, the worse the homeostatic resilience of the person, and vice versa. |
Baseline and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Body Mass Index at 12 Weeks
Time Frame: Baseline and Week 12
|
The change between the baseline and after 12-week lifestyle intervention.
Weight and height will be assessed by Seca-255 (ScalesGalore).
|
Baseline and Week 12
|
Change from Baseline in Waist Circumference at 12 Weeks
Time Frame: Baseline and Week 12
|
The change between the baseline and after 12-week lifestyle intervention.
Waist circumference will be assessed by Seca-201(ScalesGalore).
|
Baseline and Week 12
|
Change from Baseline in Hip Circumference at 12 Weeks
Time Frame: Baseline and Week 12
|
The change between the baseline and after 12-week lifestyle intervention.
Waist circumference will be assessed by Seca-201(ScalesGalore).
|
Baseline and Week 12
|
Change from Baseline in Blood Pressure at 12 Weeks
Time Frame: Baseline and Week 12
|
The change of systolic and diastolic blood pressures between the baseline and after 12-week lifestyle intervention.
Both systolic pressure and diastolic pressure will be assessed using electronic blood pressure monitor (Omron J750).
|
Baseline and Week 12
|
Change from Baseline in Heart Rate at 12 Weeks
Time Frame: Baseline and Week 12
|
The change of systolic and diastolic blood pressures between the baseline and after 12-week lifestyle intervention.
Heart rate will be assessed using Omron J750.
|
Baseline and Week 12
|
Change from Baseline in Body Composition at 12 Weeks
Time Frame: Baseline and Week 12
|
The change between the baseline and after 12-week lifestyle intervention.
Body composition will assessed using dual energy x-ray absorptiometry (DXA) (GE).
|
Baseline and Week 12
|
Change from Baseline in Energy Expenditure at 12 Weeks
Time Frame: Baseline and Week 12
|
The change between the baseline and after 12-week lifestyle intervention.
Energy expenditure will be assessed using whole room indirect calorimeter.
|
Baseline and Week 12
|
Change from Baseline in Respiratory Quotient at 12 Weeks
Time Frame: Baseline and Week 12
|
The change between the baseline and after 12-week lifestyle intervention.
Respiratory quotient will be assessed using whole room indirect calorimeter.
|
Baseline and Week 12
|
Change from Baseline in Glucose Homeostasis at 12 Weeks
Time Frame: Baseline and Week 12
|
The change between the baseline and after 12-week lifestyle intervention.
Glucose homeostasis will be assessed by Continuous Glucose Monitoring (FreeStyle Libre).
|
Baseline and Week 12
|
Change from Baseline in Glucose at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change of glucose from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in C-peptide at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change of C-peptide from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in Insulin Indices at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change of insulin indices from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in Lipid Parameters at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change of lipid parameters from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in Protein and Amino Acids Metabolites at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in Inflammatory Biomarkers and Cytokines at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in Gastrointestinal Hormones at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change in gastrointestinal hormones from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in Cell Adhesion Molecules at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change in cell adhesion molecules from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in Adipokines at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change in adipokines from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
|
Baseline and Week 12
|
Change from Baseline in Metabolomics at 12 Weeks
Time Frame: Baseline and Week 12
|
The dynamic change in metabolomics including profiling of free fatty acids and other metabolites from 0 to 30, 60, 120, 180, 240, 300 minutes pre- and post-oral mixed-nutrient dietary challenge between the baseline and after 12-week lifestyle intervention.
Metabolomics will be measured by LC-MS.
|
Baseline and Week 12
|
Single nucleotide polymorphism (SNPs)
Time Frame: Baseline
|
Mutations at specific sites will be detected by gene chip.
|
Baseline
|
Gut microbiota 16S rDNA sequencing
Time Frame: Baseline and Week 12
|
Gut microbiota 16S rDNA will be sequenced and community composition will be analyzed.
|
Baseline and Week 12
|
Change from Baseline in Body Weight at 12 Weeks
Time Frame: Baseline and Week 12
|
The change between the baseline and after 12-week lifestyle intervention.
Weight will be assessed by Seca-255 (ScalesGalore).
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Xu Lin, PhD, Institute for Nutritional Sciecnes, CAS; Hangzhou Institute for Advanced Study, UCAS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HIAS-LIMH-202302
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on General lifestyle and nutritional education
-
Azienda Ospedaliera Universitaria Integrata VeronaNot yet recruitingObesity, Pediatric
-
Coordinación de Investigación en Salud, MexicoNational Council of Science and Technology, MexicoCompleted
-
Taipei Medical UniversityMeiji Co., Ltd.CompletedMalnutrition ElderlyTaiwan
-
Abbott NutritionWithdrawn
-
Rio de Janeiro State UniversityConselho Nacional de Desenvolvimento Científico e TecnológicoCompleted
-
Hospital El EscorialUnknownADHD | Food Habits | Lifestyle-Related ConditionSpain
-
Federal University of Rio Grande do SulCompleted
-
Philipp SchuetzRecruiting
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
Boston UniversityCompleted